5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is an adenosine derivative and can be used as an intermediate for oligonucleotides synthesis.

3'-Deoxyuridine-5'-triphosphate trisodium (3'-dUTP trisodium) is a nucleotide analogue that inhibits DNA-dependent RNA polymerases I and II. 3'-Deoxyuridine-5'-triphosphate trisodium strongly and competitively inhibits the incorporations of UTP into RNA with a Ki value of 2.0 μM.

5'-O-DMT-rU is a modified nucleoside and can be used to synthesize RNA.

Fostroxacitabine bralpamide (MIV-818) is an orally active Troxacitabine-based nucleotide prodrug. Fostroxacitabine bralpamide has anticancer effects.

Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-drug of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity.

Flurocitabine is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine has antitumor activity during phase I studies in acute leukemia and solid tumors.

Bis-Pro-5FU (Compound 4) is a 5-FU precursor that confers oral bioavailability and increase the safety profile of 5-Fluorouracil (5-FU) chemotherapy regimens. 5-FU is an antineoplastic antimetabolite that is widely used for the research of colorectal and pancreatic cancer.

3-Deazauridine (DAU, NSC 126849) is a nucleoside analog that competitively inhibits cytidine triphosphate synthetase (CTP).3-Deazauridine inhibits the growth of L1210 leukemia cells when used at a concentration of 6 µM and dose-dependently reduces mortality in a mouse model of leukemia.3-Deazauridine selectively suppresses cell viability in a MYC-dependent manner in ARPE-19 cells.3-Deazauridine causes selective replication stress in MYC-overexpressing cells, which originates from MYC-driven rRNA synthesis.3-Deazauridine combined with ATR inhibitor BAY-1895344 induces synthetic lethality to MYC-overexpressing cells, and suppresses tumor growth in 3D assays and in vivo.

Thymidine Phosphorylase inhibitor 8g (hTP inhibitor 8g) is a novel potent, selective inhibitor of human thymidine phosphorylase (hTP) with IC50 of 0.12 uM; induces DNA damage measured with the alkaline comet assay in HepG2 cells; hTP inhibitor 8g (50 mg/kg/day) for two weeks (5 days/week) significantly reduced tumor growth using an in vivo glioblastoma model.

Zebularine (NSC309132, 4-Deoxyuridine) is a nucleoside analog of cytidine and inhibitor of cytidine deaminase, also inhibits DNA methylation and tumor growth both in vitro and in vivo.

6-Mercaptopurine-13C2,15N (Mercaptopurine-13C2,15N) is the 13C- and 15N-labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.

Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine, is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC50 of 2.3 μM and a Ki of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis.

2'-O,4'-C-Methyleneadenosine (LNA-A) is a locked nucleic acid (LNA) and is also an adenosine analog.

L-Cytidine is an L-configurational form of Cytidine. L-Cytidine is a pyrimidine nucleoside, a component of RNA. Cytidine can control the glial glutamate cycle, affect brain phospholipid metabolism, catecholamine synthesis and mitochondrial function.

3’-Deoxy-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

2’-O-Methyl-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

N4-Benzoyl-3’-O-methylcytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities.

DI-87 ((R)-DI-87) is a highly potent, specific, orally bioavailable deoxycytidine kinase (dCK) inhibitor with IC50 of 3.15 nM.

F-aza-T-dCyd (NSC801845) is a novel cytidine analog and is more efficacious than aza-T-dCyd in cell culture and mouse xenograft studies in HCT-116 human colon carcinoma.

JLT048 is a small molecule inhibitor of tyrosyl-DNA-phosphodiesterases 1 and 2 (TDP1 and TDP2) with IC50 of 7.7 and 32 uM, respectively.

PSB-071 (PSB071) is a small molecule inhibitor of nucleoside triphosphate diphosphohydrolases (NTPDase).

PSB-0952 (PSB0952) is a potent, selective ecto-5'-Nucleotidase (eN, CD73) inhibitor with Ki of 260 nM, >150-fold selectivity over NTPDases and P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12.